TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04677777

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PP-007 (Two doses administered 24±6 hours apart) + SOC (IVT or MT or IVT+MT)
Description: PP-007 is PEGylated carboxyhemoglobin. Eligible patients will receive two doses of PP-007 (at least 24 hours apart) to evaluate extended drug exposure along with MT and/or IVT (individually or together) as SOC to evaluate safety in AIS patients.
Study: NCT06142604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flecainide
Description: Single 300mg dose of oral flecainide
Study: NCT05399875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality virtual ruler
Description: Use of augmented reality virtual ruler to measure catheter length
Study: NCT06178549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV Self-Sampling
Description: HPV self-sampling. Participants will be provided with education regarding cervical cancer prevention and Aptima kit and instructions for self-sampling. Patient navigators will assist participants with positive HPV test results to connect with healthcare providers for follow-up screening and care.
Study: NCT04739969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Soterix Neural Navigator neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro TMS system (MagVenture, Denmark).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC
Description: The parameters in the sham arm will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study: NCT06166420

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Counseling on cervical cancer screening followed by home-based HPV self-sampling test proposal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Counseling on cervical cancer screening followed invitation to screen at Dschang District Hospital.
Study: NCT05954078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX adjuvant chemotherapy
Description: mFOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6/XELOX adjuvant chemotherapy
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 400mg/m2 infusion, and 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles or XELOX (oxaliplatin 130mg/m2, ivgtt, Q3w; capecitabine 1000mg/m2, p.o, Q3w) for 8 cycles
Study: NCT05578573

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARAHOC device
Description: After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by KARAHOC device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiocatheter
Description: After leaving a mark on the part where the puncture is to be performed using a pen, sterilization dressing are performed, local anesthesia is performed aseptic then ascites paracentesis by angiocatheter
Study: NCT05056337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 4 MG Oral Capsule [Lenvima]
Description: patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: patients will be treated with lenvatinib in combination with toripalimab and TACE (on demand)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Hepatic arterial chemoembolization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: Hepatic arterial chemoembolization
Study: NCT04956406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing for Adult Kidney Transplant Recipients
Description: Motivational interviewing with individual sessions are planned to be conducted 3 times. Planned motivational interviews will be implemented the intervention group who are within 3th month, 4th month, 5th month and 6th month. Motivational interviewing will planned last 15-30 minutes with an interval of 10 days. The first interview will be performed face-to-face at the transplant outpatient clinic and the second and third ones will be phone interviews

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: The control group will be provided with routine care( face-to-face care standard training) by the nurse educator at the transplant outpatient clinic.
Study: NCT04422847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D obturator
Description: Based on this 3D visualization of precise anatomical conditions in the oral cavity, a form (negative unique impression of the upper jaw and palato-alveolar conditions) for casting of a protective obturator (splint), used during intubation to cover the defect of the alveolar arch and palate will be created on a 3D printer
Study: NCT04645290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group: Educational Intervention KARER
Description: Multicomponent and interdisciplinary intervention on the care ability and burden of family caregivers. It consists of:~Virtual componet~* Module 0: the introduction~* Module 1: called Identifying my role as a caregiver~* Module 2: called Strategies to strengthen care~* Module 3: called Strengthening my caring skills~Face-to-face componed - Two seasons of 4 hours each~Simulation component~- One season of practices abilities of 4 hours.
Study: NCT03909321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beach tennis training group
Description: Beach Tennis Training Group (BTG) will perform two sessions of 40-60 min of beach tennis during 12 weeks. BT sessions will be composed by a warm up of 5-10 min of BT technical exercises (i.e., serve, volley, forehand and backhand exercises) followed by 3 BT small games of 10-15 min each.
Study: NCT06294171

Intervention type: DEVICE
Group type: OTHER
Intervention: measurement of alveolar ridge width
Description: the surgical procedure started with envelop flap reflection. A mucoperiosteal elevator was used to reflect the buccal and palatal flaps that were enough to expose the crestal part of alveolar ridge with clear visibility and accessibility. Measuring the width of the alveolar ridge 1 mm below the crest using bone caliber. Using piezoelectric surgery unit (Piezosurgery Ultrasonic® mectron, Italy), a horizontal crestal cut was produced along the crest of the bone. The cut depth extended into the same depth of the final dental implant to be inserted and then Versah Drills will be used in a successive manner and under copious irrigation with chilled sterile normal saline.We will measure the rate of ridge expansion by bone caliber to determine the efficacy of combining Versah drills with piezo surgery in expanding narrow alveolar bone.
Study: NCT05953428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Sparing Anesthesia Protocol (OSA)
Description: OSA protocol will include boluses of dexmedetomidine and ketamine at anesthesia induction, followed by a ketamine infusion that will continue until PACU discharge. Another bolus of ketamine will be administered upon surgical incision and another dexmedetomidine bolus will be given at surgical closure to reduce the use of opioids.

Intervention type: OTHER
Group type: OTHER
Intervention: Opioid Based Anesthesia Protocol (OBA)
Description: The OBA group will be administered a saline infusion at the same rate of the ketamine infusion (only while in the PACU) up until PACU discharge so that surgeons, patients, and PACU nurses will be blinded. The OBA group will be administered fentanyl 100 mcg IV for anesthesia induction followed by 50 mcg IV boluses when heart rate or systolic blood pressure is 20% above baseline throughout the case.
Study: NCT05093283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: Virtual Reality Glasses
Study: NCT04604483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS
Description: Patients meeting the criteria are treated with PTNS and are evaluated at 3 months and 1 year after end of treatment.
Study: NCT04607642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-001
Description: BMX-001 consists of a porphyrin ring with pyridyl groups attached at each of the four methane bridge carbons. The nitrogen in the pyridyl ring is at the 2 position and has a side chain consisting of six carbons with an ether linkage. A manganese atom is chelated into the porphyrin ring and is the active center of the molecule. This molecule is an enzymatic scavenger of free radical species operating at close to diffusion-limited rates.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: Treatment plan should include a continuous course of treatment delivered as single daily fractions of 2.0 to 2.1 Gy with a cumulative radiation dose between 60 Gy and 70 Gy. Planned radiation treatment volumes must include at least two oral mucosal sub-sites (buccal mucosa, retromolar trigone, floor of mouth, tongue, soft palate, hard palate) with a portion of each site receiving at least 50 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin is an IV chemotherapeutic agent approved to treat head and neck cancers. Cisplatin will be administered per institution's standard of care practice. Common standard of care practice includes dosing cisplatin at 100mg/m2 IV q21 days starting on Day 1 of RT for 2-3 doses or dosing cisplatin at 40 mg/m2 IV each week of RT for 6-7 total doses. Cisplatin will be infused per institutional guidelines.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo to be used in this study is 0.9% Sodium Chloride Injection, USP.
Study: NCT06163573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-TEC
Description: Implantation of an autologous tissue engineered cartilage graft in the patellofemoral joint for treatment of osteoarthritis.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: Injection of an autologous Conditioned Plasma ACP® on the basis of one injection per week for three consecutive weeks.~Conditioned Plasma ACP®, Arthrex, one injection per week for three consecutive weeks.
Study: NCT04853251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUSVIMO PDS Implant
Description: The ranibizumab 100 mg/mL will be delivered via PDS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUCENTIS (ranibizumab injection)
Description: Ranibizumab (intravitreal 0.5-mg intravitreal injections of 10 mg/mL formulation) will be used in the study eye as supplemental treatment. If a participant discontinues study treatment, he/she may start receiving intravitreal ranibizumab injections in the study eye, per investigator's discretion.
Study: NCT05593835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: METHIS Platform
Description: The METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Care Training Program
Description: The training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
Study: NCT04722042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: place-based mapping
Description: Adjusting the electric frequency filters to align with the cochlear place frequency

Intervention type: OTHER
Group type: OTHER
Intervention: default mapping
Description: Default frequency filter assignments
Study: NCT04812223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed umbilical cord clamping
Description: The umbilical cord will be clamped 60 seconds after the baby is born.
Study: NCT05131581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changed clinical context
Description: Changed clinical context: from midwifery clinic to youth clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changed clinical context
Description: Changed clinical context: from midwifery clinic to youth clinic

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changed clinical context
Description: Changed clinical context: from midwifery clinic to youth clinic
Study: NCT04812223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early umbilical cord clamping
Description: The umbilical cord will be clamped 15 seconds after the baby is born.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Milking of the umbilical cord
Description: The cord will be milked 5 times with 2 seconds milking, then letting 2 seconds for spontaneous blood flow.
Study: NCT05131581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra time allotted
Description: Extra time allotted for each visit for CST

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra time allotted
Description: Extra time allotted for each visit for CST

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLP-information
Description: Midwife-initiated discussion of the Reproductive Life Plan
Study: NCT05358873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human IgG1 anti-SARS-CoV-2 antibody cocktail
Description: Hypromellose-based nasal spray solution containing human IgG1 anti-SARS-CoV-2 antibody cocktail
Study: NCT05914597

Intervention type: OTHER
Group type: OTHER
Intervention: Setting up home delivery of Colon capsule endoscopy
Description: Feasibility study of home delivery of CCE
Study: NCT05663112

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Sentinel lymph node biopsy will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breast massage
Description: Breast massage will be performed for a duration of 5 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blue dye injection
Description: Isosulfan blue dye will be injected in the subareolar region of the breast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blue dye injection
Description: Isosulfan blue dye will be injected in the subareolar region of the breast
Study: NCT06121817

Intervention type: OTHER
Group type: OTHER
Intervention: Food/meal intervention
Description: 2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food/meal intervention
Description: 2 types of exotic fruits, durian and banana, are the study test meals. Both isocaloric test meals are performed at breakfast. All subjects are required to consume the entire meal within 10 minutes.
Study: NCT05800717

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCI Self-Management for AIS D
Description: An individually administered, self-management intervention for Veterans with AIS D spinal cord injury.
Study: NCT05877118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Overdose Education (EOE)
Description: EOE was adapted by Co-I Dr. Monique Miley at HHC's premier addiction hospital-The Rushford Center. It follows the guidelines set by Co-PI Jonathan Craig Allen when working with opioid patients reluctant to obtain naloxone:~* Express confidence in naloxone~* Provide a clear statement about suitability (You are an excellent candidate for naloxone)~* Begin discussion using presumptive language (You must be ready for an overdose)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard education
Description: Written instructions that accompany a kit prescription in many EDs throughout the country.
Study: NCT04900259

Intervention type: BEHAVIORAL
Intervention: COVID-19 pandemic
Description: Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.

Intervention type: BEHAVIORAL
Intervention: COVID-19 pandemic
Description: Patients diagnosed with primary bladder cancer by transurethral resection in the urology clinic during and before the COVID-19 pandemic will be retrospectively evaluated and compared.
Study: NCT05674539

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine and Busulfan
Description: Fludarabine with total dose of 150 mg/m\^2 in combination with Busulfan with total dose of 6.4 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Melphalan
Description: Fludarabine with total dose of 150 mg/m\^2 in combination with Melphalan with total dose of 140 mg/m\^2
Study: NCT05358873

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT05158491

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.
Study: NCT04618835

Intervention type: DIAGNOSTIC_TEST
Intervention: 40-Steps-test
Description: 40 steps performed on the spot
Study: NCT05562336

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: Optical coherence tomography (OCT) is a noninvasive imaging method that uses reflected light to create pictures of the back of your eye
Study: NCT05871697

Intervention type: OTHER
Intervention: Measurement of multifidus and gastrocnemius muscle thickness with Ultrasound
Description: To measure multifidus and gastrocnemius muscle thickness using ultrasound imaging, the following steps are typically followed. First, the patient is positioned appropriately to allow access to the muscles to be imaged. For example, the patient may lie prone for imaging of the lumbar multifidus or sit with the leg extended for imaging of the gastrocnemius. Next, a trained clinician or technician places an ultrasound probe on the skin over the target muscle and adjusts the settings on the ultrasound machine to optimize the image quality. The probe is then moved around to obtain different views of the muscle, and the images are stored for later analysis. To measure muscle thickness, the clinician or technician identifies the muscle fascia on the ultrasound image and measures the distance between the fascia and the underlying bone or tissue. This measurement provides an estimate of the muscle thickness.

Intervention type: OTHER
Intervention: Berg Balance Scale
Description: The Berg Balance Scale is a clinical assessment tool used to measure an individual's ability to maintain balance during various functional tasks. The test includes 14 items, such as standing unsupported, reaching forward, turning, and standing on one leg. Each item is scored on a 5-point scale, ranging from 0 (unable to perform the task) to 4 (able to perform the task independently and safely). The scores for each item are summed to provide a total score, with a maximum possible score of 56.
Study: NCT05936736

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: prostate SBRT
Description: Patients with prostate cancer will be treated with high-dose SBRT to prostate and seminal vesicles, delivered in one fraction, sparing the urethra and generating a dose distribution similar to HDR brachytherapy
Study: NCT05091814

Intervention type: RADIATION
Intervention: radiotherapy
Description: patients who recieved radiotherapy after surgical removal of the tumor
Study: NCT05921903

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSVPreF3 OA Investigational Vaccine
Description: The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Investigational Vaccine
Description: The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Investigational Vaccine
Description: The investigational vaccine will be administered intramuscularly as 1 dose to RSV_IC_1 and RSV_HA groups, and 2 doses to RSV_IC_2 group).